Experimental models for the study of pulmonary fibrosis: Current usefulness and future promise;Modelos experimentales para el estudio de la fibrosis pulmonar: Utilidad práctica actual y futura

Archivos de Bronconeumologia

Volumn 43, Issue 9, 2007, Pages 501-507

  Molina Molina, María ^a   Pereda, Javier ^a   Xaubet, Antoni ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Experimental studies; Interstitial lung disease; Pulmonary fibrosis

Indexed keywords

DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; EXPERIMENTAL STUDY; FIBROSING ALVEOLITIS; HUMAN; LUNG FIBROSIS; LUNG PARENCHYMA; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW;

EID: 36049003043     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13109471     Document Type: Review

References (85)

1. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:227-304.
2. Xaubet A, Ancochea J, Blanquer R, Montero C, Morell F, Rodríguez-Becerra E, et al. Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas. Arch Bronconeumol. 2003;39:580-600.
3. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136-51.
4. Phan SH, Thrall RS, Ward PA. Bleomycin-induced pulmonary in rats, biochemical demonstration of increased rate of collagen synthesis. Am Rev Respir Dis. 1980;121:501-6.
5. Chua F, Gauldie J, Laurent GH. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol. 2005;33:9-13.
6. Antonini JM, Starks K, Roberst JR, Millecchia L, Yang HM, Rao KM. Changes in F-actin organization induced by hard metal particle exposure in rat pulmonary epithelial cells using laser scanning confocal microscopy. In Vitr Mol Toxicol. 2000;13:5-16.
7. Fleischman RW, Baker JR, Thompson GR, Schaeppi UH, Illievski VR, Cooney DA, et al. Bleomycin-induced interstitial pneumonia in dogs. Thorax. 1971;26:675-82.
8. Ebihara T, Venkatesan N, Tanaka R, Ludwig MS. Changes in extracellular matrix and tissue viscoelasticity in bleomycin-induced lung fibrosis. Temporal aspects. Am J Respir Crit Care Med. 2000;162:1569-76.
9. Gharaee-Kermani M, Ullenbruch M, Phan SH. Animal models of pulmonary fibrosis. Methods Mol Med. 2005;117:251-9.
10. Usuki J, Fukuda Y. Evolution of three patterns of intra-alveolar fibrosis produced by bleomycin in rats. Pathol Int. 1995;45:552-64.
11. Zhang K, Flanders KC, Phan SH. Cellular localization of transforming growth factor-beta expression in bleomycin-induced pulmonary fibrosis. Am J Pathol. 1995;147:352-61.
12. Munger JS, Huang X, Kawadatsu H, Griffiths MJ, Dalton SL, Wu J, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96:319-28.
13. Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH. Dual roles of IL-4 in lung injury and fibrosis. J Immunol. 2003;170:2083-92.
14. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med. 1997;156:600-8.
15. Serrano-Mollar A, Closa D, Cortijo J, Morcillo EJ, Prats N, Gironella M, et al. P-selectin upregulation in bleomycin induced lung injury in rats: effect of N-acetyl-L-cysteine. Thorax. 2002;57:629-34.
16. Kolb M, Margetts PJ, Galt T, Sime PJ, Xing Z, Schmidt M, et al. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med. 2001;163:770-7.
17. Molina-Molina M, Serrano-Mollar A, Bulbena O, Fernández-Zabalegui L, Closa D, Marín-Arguedas A, et al. Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis Thorax. 2006;61:604-10.
18. Haston CK, Wang M, Dejournett RE, Zhou X, Ni D, Gu X, et al. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum Molt Genet. 2002;11:1855-63.
19. Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M, Kawasaki M, et al. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol. 1997;17:272-8.
20. Li X, Zhang H, Soledad-Conrad V, Zhuang J, Uhal BD. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol Lung Cell Mol Physiol. 2003;284:L501-L7.
21. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 2004;114:438-46.
22. Harrison JH Jr, Lazo JS. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J. Pharmacol Exp Ther. 1987;243:1185-94.
23. Uhal BD, Wang R, Laukka J, Zhuang J, Soledad-Conrad V, Filippatos G. Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharmacol Toxicol. 2003;92:81-7.
24. Taylor MD, Roberts JR, Hubbs AF, Reasor MJ, Antonini JM. Quantitative image analysis of drug-induced lung fibrosis using laser scanning confocal microscopy. Toxicol Sci. 2002;67:295-302.
25. Card JW, Racz WJ, Brien JF, Margolin SB, Massey TE. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci. 2003;75:169-80.
26. Barbarin V, Arras M, Misson P, Delos M, McGarry B, Phan SH, et al. Characterization of the effect of interleukin-10 on silica-induced lung fibrosis in mice. Am J Respir Cell Mol Biol. 2004;31:78-85.
27. Coin PG, Osornio-Vargas AR, Roggli VL, Brody AR. Pulmonary fibrogenesis after three consecutive inhalation exposures to chrysotile asbestos Am J Respir Crit Care Med. 1996;154:1511-9.
28. Pauluhn J, Baumann M, Hirth-Dietrich C, Rosenbruch M. Rat model of lung fibrosis: comparison of functional, biochemical, and histopathological changes 4 months after single irradiation of the right hemithorax. Toxicology. 2001;161:153-63.
29. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005;201:925-35.
30. Carpenter M, Epperly MW, Agarwal A, Nie S, Hricisak L, Niu Y, et al. Inhalation delivery of manganese superoxide dismutase-plasmid/liposomes protects the murine lung from irradiation damage. Gene Ther. 2005;12:685-93.
31. Budinger GR, Mutlu GM, Eisenbart J, Fuller AC, Bellmeyer AA, Baker CM, et al. Proapoptotic Bid is required for pulmonary fibrosis. Proc Natl Acad Sci U S A. 2006;103:4604-9.
32. Bonner JC, Rice AB, Ingram JL, Moomaur CR, Nyska A, Bradbury A, et al. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am J Pathol. 2002;161:459-70.
33. Miyazaki H, Kuwano K, Yoshida K, Maeyama T, Yoshimi M, Fujita M, et al. The perforin mediated apoptotic pathway in lung injury and fibrosis J Clin Pathol. 2004;57:1292-8.
34. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, et al. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med. 2002;165:229-35.
35. Liu JY, Brody AR. Increased TGF-beta 1 in the lungs of asbestos-exposed rats and mice: reduced expression in TNF- alpha receptor knockout mice. J Environ Pathol Toxicol Oncol. 2001;20:97-108.
36. Rim KT, Park KK, Sung JH, Chung YH, Han JH, Cho KS, et al. Gene-expression profiling using suppression-subtractive hybridization and cDNA microarray in rat mononuclear cells in response to welding-fume exposure. Toxicol Ind Health. 2004;20:77-88.
37. Blundell R, Kaminski N, Harrison D. Increase in p21 expression independent of the p53 pathway in bleomycin-induced lung fibrosis. Exp Mol Pathol. 2004;77:231-7.
38. Inoshima I, Kuwano K, Hamada N, Hagimoto N, Yoshimi M, Maeyama T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1038-L44.
39. Dave NB, Kaminski N. Analysis of microarray experiments for pulmonary fibrosis. Methods Mol Med. 2005;117:333-58.
40. Kijiyama N, Ueno H, Sugimoto I, Sasaguri Y, Yatera K, Kido M, et al. Intratracheal gene transfer of tissue factor pathway inhibitor attenuates pulmonary fibrosis. Biochem Biophys Res Commun. 2006;339:1113-9.
41. Kaminski J, Allard JD, Pittet F, Zuo F, Griffiths MJD, Morris D, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A. 2000;97:1778-83.
42. Renzoni EA, Abraham DJ, Howat S, Shi-Wen X, Sestini P, Bou-Gharios G, et al. Gene expression profiling reveals novel TGFβ targets in adult lung fibroblasts. Respir Res. 2004;5:1-12.
43. Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006;173:188-98.
44. Arras M, Louahed J, Simoen V, Barbarin V, Misson P, Van den Brule S, et al. B lymphocytes are critical for lung fibrosis control and prostaglandin E2 regulation in IL-9 transgenic mice. Am J Respir Cell Mol Biol. 2006;34:573-80.
45. Xaubet A, Marín-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, et al. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:431-5.
46. Zhang K, Phan SH. Cytokines and pulmonary fibrosis. Biol Signals. 1996;5:232-9.
47. Li X, Rayford H, Uhal BD. Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol. 2003;163:2523-30.
48. Xu YD, Hua J, Mui A, O'Connor R, Grotendorst G, Khalil N. Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2003;285:L527-L39.
49. Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2004;286:L156-L64.
50. Koloksick JE, Toews GB, Jakubzick C, Hogaboam C, Moore TA, McKenzie A, et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol. 2004;172:4068-76.
51. Matsuyama W, Watanabe M, Shirahama Y, Mitsuyama H, Higashimoto I, Osame M, et al. Discoidin domain receptor 1 contributes to the survival of lung fibroblast in idiopathic pulmonary fibrosis. Am J Pathol. 2006;168:866-77.
52. Ramos C, Montaño M, García-Álvarez J, Ruiz V, Uhal BD, Selman M, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol. 2001;24:591-8.
53. Liu X, Sun SQ, Ostrom RS. Fibrotic lung fibroblasts show blunted inhibition by cAMP due to deficient cAMP response element-binding protein phosphorylation. J Pharmacol Exp Ther. 2005;315:678-87.
54. 1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 2005;6:56.
55. Wang R, Alam G, Zagariya A, Gidea C, Pinillos H, Lalude O, et al. Apoptosis of lung epithelial cells in response to TNF-α requires angiotensin generation de novo. J Cell Physiol. 2000;185:253-9.
56. Lichtenberger FJ, Montague C, Hunter M, Frambach G, Marsh CB. NAC and DTT promote TGF-beta1 monomer formation: demonstration of competitive binding. J Inflamm (Lond). 2006;11: 3:7.
57. Ishida T, Tsukada H, Hasegawa T, Yoshizawa H, Gejyo F. Matrix metalloproteinase-1 activation via plasmin generated on alveolar epithelial cell surfaces. Lung. 2006;184:15-9.
58. Adamson IH, Young L, Bowden DH. Relationship of alveolar epithelial injury and repair to the induction of pulmonary fibrosis. Am J Pathol. 1988;130:377-83.
59. Ye Q, Chen B, Tong Z, Nakamura S, Sarria R, Costabel U, et al. Thalidomide partially reduces IL-18, IL-8 and TNF-{alpha} release from alveolar macrophages in interstitial lung disease. Eur Respir J. 2006;28:824-31.
60. Mora AL, Torres-González E, Rojas M, Corredor C, Ritzenthaler J, Xu J, et al. Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respir Cell Mol Biol. 2006;35:466-73.
61. Portnoy J, Pan T, Dinarello CA, Shannon JM, Westcott JY, Zhang L, et al. Alveolar type II cells inhibit fibroblast proliferation: role of IL-1?. Am J Physiol Lung Cell Mol Physiol. 2006;290:L307-L16.
62. Morishima Y, Nomura A, Uchida Y, Noguchi T, Sakamoto T, Ishii Y, et al. Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir Cell Mol Biol. 2001;24:1-11.
63. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, et al. Vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med. 2006;173:781-92.
64. Li X, Shu R, Filippatos G, Uhal BD. Apoptosis in lung injury and remodeling. J Appl Physiol. 2004;97:1535-42.
65. 1 en la fibrosis pulmonar idiopática. Arch Bronconeumol. 2006;42:380-3.
66. Gauldie J. Pro: inflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002;165:1205-6.
67. Strieter RM. Con: inflammatory mechanisms are not a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002;165:1206-7.
68. Calabrese F, Giacometti C, Rea F, Loy M, Valente M. Idiopathic interstitial pneumonias: primum movens: epithelial, endothelial or whatever. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:S15-S23.
69. Keane MP, Strieter RM, Belperio JA. Mechanisms and mediators of pulmonary fibrosis. Crit Rev Immunol. 2005;25:429-63.
70. Parra ER, David YR, Da Costa LR, Ab'Saber A, Sousa R, Kairalla RA, et al. Heterogeneous remodeling of lung vessels in idiopathic pulmonary fibrosis. Lung. 2005;183:291-300.
71. Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164: 2239-42.
72. Keane MP, Arenberg DA, Lynch JP, Whyte RI, Lannettoni MD, Burdick MD, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 1997;159:1437-44.
73. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc. 2006;3:293-8.
74. Doran P, Egan JJ. Herpesviruses: a cofactor in the pathogenesis of idiopathic pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 2005;289:L709-L10.
75. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Sillery JK, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27:136-42.
76. Lee HL, Ryu JH, Wittmer MH, Harman TE, Lymp JF, Tazelaar HD, et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest. 2005;127:2034-41.
77. Hodgson U, Pulkkinen V, Dixon M, Peyrard-Janvid M, Rehn M, Lahermo P, et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am J Hum Genet. 2006;79:149-54.
78. Nogee LM. Genetics of pediatric interstitial lung disease. Curr Opin Pediatr. 2006;18:287-92.
79. Elford J, Fitch P, Kaminski E, McGavin C, Wells IP. Five cases of sarcoidosis in one family: a new immunological link? Thorax. 2000;55:343-4.
80. Kruit A, Grutters JC, Ruven HJ, Van Moorsel CH, Weiskirchen R, Mengsteab S, et al. Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest. 2006;129:1584-91.
81. Falfan-Valencia R, Camarena A, Juárez A, Becerril C, Montano M, Cisneros J, et al. Major histocompatibility complex and alveolar epithelial apoptosis in idiopathic pulmonary fibrosis. Hum Genet. 2005;118:235-44.
82. Vasakova M, Striz I, Slavcev A, Jandova S, Kolesar L, Sulc J. Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. Tissue Antigens. 2006;67:229-32.
83. Lawson WE, Gran SW, Ambrosini V, Womble KE, Dawson EP, Lane KB, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax. 2004;59:977-80.
84. Wurfel MM, Raghu G. Genetics of pulmonary fibrosis. Semin Respir Crit Care Med. 2002;23:177-87.
85. Ancochea J, Antón E, Casanova A. New therapeutic strategies in idiopathic pulmonary fibrosis. Arch Bronconeumol. 2004;40 Supl 6:16-22.